The combination pemetrexed–carboplatin could be a valuable treatment option in elderly patients, as indicated by this phase II trial. Neutropenia was the most common toxicity. The objective tumor response rate is within the range of data reported for pemetrexed–carboplatin in the general NSCLC population.
We report a rare case of lung adenocarcinoma in which micropapillary components were considered to cause stump recurrence. This case illustrates the importance of careful pathological investigation when an autosuture instrument is used for a partial resection in a case of lung adenocarcinoma with micropapillary components. In such cases, it is particularly important to clarify if micropapillary components are floating near a stump.
Recent discovery of ROS1 gene fusion in a subset of lung cancers has raised clinical interest, because ROS1 fusion-positive cancers are reportedly sensitive to kinase inhibitors. To better understand these tumors, we examined surgically resected non-small cell lung cancers.
Worldwide lung cancer incidence is decreasing or leveling off among men, but rising among women. Sex differences in associations of tobacco carcinogens with lung cancer risk have been hypothesized, but the epidemiologic evidence is conflicting. We tested sex-smoking interaction in association with lung cancer risk within a population-based case-control study, the Environment and Genetics in Lung Cancer Etiology (EAGLE) Study. Our findings do not support a higher female susceptibility to tobacco-related lung cancer.
The use of adjuvant radiotherapy in patients with pT3 prostate cancer subsequent to radical prostatectomy is safe, according to 10-year follow-up results presented at the American Society of Clinical Oncology (ASCO) 2013 Genitourinary Cancers Symposium. Those patients in the trial who were treated with adjuvant radiotherapy had a 21% absolute increase in biochemical non-evidence of disease compared with patients who were assigned to wait-and-see treatment after surgery, adding to previous evidence of the safety of radiotherapy in the long-term.
Radiation therapy is traditionally thought to suppress the immune system. However, it may also stimulate immune cells that can fight against tumor growth. A recent study found that increased levels of the immune cell proteins CD4 and CD8 correlated with improved survival in non-small cell lung cancer (NSCLC) patients who had received radiation therapy after tumor removal. The results suggest that immune cell protein levels could be used to help determine prognosis for patients receiving such “adjuvant therapy.”
During median follow-up of 6.4 years, 31.3% of the localized cancers were upgraded. The proportion of men with upgraded tumors increased over time, D. Andrew Loblaw, MD, reported here at the ASCO GU symposium. “This increase over time was not statistically significant, but it allows for some hypothesis generation.” A panel of experts debated the result and the future of active surveillance for low-risk prostate cancer patients.
Phase I and pre-clinical results with ODM-201, the ARADES trial show the drug is well tolerated, with no significant treatment-related adverse events. Prostate specific antigen (PSA) response was seen in 81% of 21 treatmnent naive patients and 92% achieved a greater than 50% PSA decrease. For post-abiraterone, post-chemo patients this decrease was seen in 67% of patients.
There is benefit to radical prostatectomy (RP) in prostate cancer patients, evenin the presence of screening. But, the benefit is limited to a subgroup of patients and can take years to become evident according to the study which analyzed the results of the Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) and the U.S. Prostate Cancer Intervention Versus Observation Trial (PIVOT) trials.